PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1532783
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1532783
3D Bioprinting in Medical Market size was valued at USD 1,202.90 Million in 2023, expanding at a CAGR of 15.90% from 2024 to 2032.
3D Bioprinting in Medicine represents technology for tissue engineering and regenerative medicine. It involves the use of biocompatible inks that contain living cells to produce three-dimensional tissue constructs. This method enables the development of complex tissues in vitro, replicating native structures and functionalities. The potential applications of 3D Bioprinting are vast, including advancements in drug discovery, personalized medicine, and potentially, the creation of transplantable organs. This technology has the potential to revolutionize healthcare by addressing organ donor shortages and enhancing treatment efficacy. The process of 3D bioprinting begins with the acquisition of CT or MRI scans of the target organ, which are then translated into a 3D blueprint using specialized software on a computer. This blueprint integrates detailed histological data obtained from microscopic analysis, resulting in a comprehensive layer-by-layer model of the organ. The finalized 3D model and material specifications are inputted into the bioprinter, which deposits biomaterial onto a platform in a precise layer-by-layer manner. Once the printing is complete, the organ is transferred to an incubator where it undergoes an incubation period to settle and stabilize, promoting the development of a functional and viable organ.
3D Bioprinting in Medical Market- Market Dynamics
Increased investment in research and development, the rising prevalence of chronic diseases to propel market demand
The growth of the 3D bioprinting in medical market is driven by increased investment in research, the growing prevalence of chronic diseases, and advancements in 3D bioprinting technology. For instance, a report from the National Association of Chronic Disease Directors in 2022 highlighted that nearly 3 out of 5 adult Americans have at least one chronic disease, underscoring the need for innovative medical solutions. Applications of 3D bioprinting in healthcare, such as tissue engineering, 3D cell culture and regenerative medicine, also contribute significantly to market expansion. This technology holds promise for creating functional tissues and organs for transplantation, addressing the critical shortage of donor organs. Collaborations, such as the agreement between CELLINK and CollPlant Biotechnologies in March 2022, further stimulate market growth by combining expertise and resources in advancing bioprinting capabilities. Moreover, ongoing technological advancements in 3D bioprinting, including improvements in precision, speed, resolution, and bioink formulations, present opportunities for market growth. For example, CELLINK introduced CELLINK Vivoink in October 2023, a medical-grade bioink tailored to support researchers in clinical translational journeys, highlighting continuous innovation in regenerative medicine and tissue engineering. These advancements underscore the evolving trends shaping the 3D bioprinting landscape in medicine.
3D Bioprinting in Medical Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 15.90% over the forecast period (2024-2032)
Based on Product Type segmentation, consumables, and accessories were predicted to show maximum market share in the year 2023
Based on Technology segmentation, inkjet-based bioprinting was the leading type in 2023
On the basis of region, North America was the leading revenue generator in 2023
The Global 3D Bioprinting in Medical Market is segmented on the basis of Product Type, Technology, Application, End Use, and Region.
The market is divided into three categories based on Product Type: Bioprinters, Consumables and accessories, and Software and services. In 2023, the consumables and accessories segment emerged as the dominant force in the global 3D bioprinting in the medical market and is projected to maintain the highest Compound Annual Growth Rate (CAGR) throughout the forecast period. This growth is primarily attributed to an increasing demand for specialized biomaterials and supportive accessories, alongside continuous advancements in bioprinting technology.
The market is divided into three categories based on Technology: Extrusion-based bioprinting, inkjet-based bioprinting and Laser-assisted bioprinting. Within the market segments, inkjet-based bioprinting held the largest share in 2023 and is anticipated to exhibit the highest CAGR during the forecast period. This dominance is driven by its precision, high-resolution capabilities, and versatility in accommodating a wide range of bioink formulations.
3D Bioprinting in Medical Market- Geographical Insights
This market operates on a global scale, encompassing North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. Customer nations further refine the market based on their location. North America led the global 3D bioprinting in the medical market in 2022 and is expected to sustain its leadership position in the coming years. This region benefits from the presence of key industry players such as 3D Systems Corporation and Organovo Holdings, Inc., as well as advanced manufacturing technologies in 3D bioprinting. The robust infrastructure, substantial investments in research and development, and supportive regulatory environment further foster the growth of 3D bioprinting technologies in North America.
Companies in the 3D bioprinting market pursue strategies focused on collaboration, innovation, and enhancing applications. Innovation remains a cornerstone strategy, with firms continuously advancing bioprinting technologies to improve precision, resolution, and the range of compatible biomaterials. Companies also prioritize expanding the applications of 3D bioprinting across various sectors of healthcare, including personalized medicine, tissue engineering, and regenerative medicine. Such strategies not only drive market growth but also foster the development of novel therapeutic solutions and enhance the capabilities of 3D bioprinting to address complex healthcare challenges.
In October 2023, Carcinotech and CELLINK announced partnership to develop and commercialize advanced protocols for biofabricating 3D bioprinted tumor models. These partnerships aim to enhance the accuracy of cancer cell line models, accelerate drug development processes, reduce costs, and increase overall efficiency.
GLOBAL 3D BIOPRINTING IN MEDICAL MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS
REGEMAT 3D
BICO
Cyfuse Biomedical K.K.
Advanced Solutions, Inc.
Organovo Holdings, Inc.
Desktop Metal, Inc.
Shining 3D
Medprin
3D Systems Corporation
CollPlant Biotechnologies
Others